Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 10 2024 - 3:06PM
UK Regulatory
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
COPENHAGEN, Denmark; September 10, 2024 –
Genmab A/S (Nasdaq: GMAB) will increase
its share capital by 11,729 shares as a consequence of the exercise
of employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
4,623 shares at DKK 1,025.00,
3,656 shares at DKK 1,032.00,
561 shares at DKK 1,050.00,
1,645 shares at DKK 1,334.50,
1,015 shares at DKK 1,432.00, and
229 shares at DKK 1,615.00.
Proceeds to the company are approximately DKK 13.1 million. The
increase corresponds to approximately 0.02% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 198
of February 26, 2024, it is hereby announced, that the total
nominal value of Genmab A/S' share capital after the capital
increase is DKK 66,176,831 which is made up of 66,176,831 shares of
a nominal value of DKK 1 each, corresponding to 66,176,831
votes.
About Genmab
Genmab is an international biotechnology company with a core
purpose of guiding its unstoppable team to strive toward improving
the lives of patients with innovative and differentiated antibody
therapeutics. For 25 years, its passionate, innovative and
collaborative team has invented next-generation antibody technology
platforms and leveraged translational, quantitative and data
sciences, resulting in a proprietary pipeline including bispecific
T-cell engagers, antibody-drug conjugates, next-generation immune
checkpoint modulators and effector function-enhanced antibodies. By
2030, Genmab’s vision is to transform the lives of people with
cancer and other serious diseases with knock-your-socks-off
(KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors
included in Genmab’s most recent Annual Report on Form 20-F and
other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at
www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following
trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination
with the Y-shaped Genmab logo®;
HuMax®;
DuoBody®;
HexaBody®;
DuoHexaBody®,
HexElect® and
KYSO®.
Company Announcement no. 56
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
- 100924_CA56_Final_Warrant Exercise
Genmab AS (TG:GE9)
Historical Stock Chart
From Oct 2024 to Nov 2024
Genmab AS (TG:GE9)
Historical Stock Chart
From Nov 2023 to Nov 2024
